Johnson & Johnson – Capital Expenditure

Quarterly charts & data from official filings

Timeframe

Capital expenditure

Capital expenditureTable view

Earnings release date
Capital expenditure
Earnings release date:15 Jul. 26
Capital expenditure:
1,321,000,000 $+25.9%
Earnings release date:14 Apr. 26
Capital expenditure:
1,049,000,000 $-42.9%
Earnings release date:21 Jan. 26
Capital expenditure:
1,837,000,000 $+58.8%
Earnings release date:14 Oct. 25
Capital expenditure:
1,157,000,000 $+10.9%
Earnings release date:16 Jul. 25
Capital expenditure:
1,043,000,000 $+31.2%
Earnings release date:15 Apr. 25
Capital expenditure:
795,000,000 $-50.7%
Earnings release date:22 Jan. 25
Capital expenditure:
1,612,000,000 $+56.7%
Earnings release date:15 Oct. 24
Capital expenditure:
1,029,000,000 $+5.4%
Earnings release date:17 Jul. 24
Capital expenditure:
976,000,000 $+20.9%
Earnings release date:16 Apr. 24
Capital expenditure:
807,000,000 $-49.2%
Earnings release date:23 Jan. 24
Capital expenditure:
1,589,000,000 $+64.3%
Earnings release date:17 Oct. 23
Capital expenditure:
967,000,000 $-14.0%
Earnings release date:20 Jul. 23
Capital expenditure:
1,124,000,000 $+30.2%
Earnings release date:18 Apr. 23
Capital expenditure:
863,000,000 $-45.6%
Earnings release date:24 Jan. 23
Capital expenditure:
1,587,000,000 $+66.7%
Earnings release date:18 Oct. 22
Capital expenditure:
952,000,000 $+10.3%
Earnings release date:19 Jul. 22
Capital expenditure:
863,000,000 $

Revenue by segment

Revenue by segmentTable view

Earnings release date
Consumer Health (→ KVUE)
Innovative Medicine
MedTech
Total
Earnings release date:15 Jul. 26
Consumer Health (→ KVUE):
–
Innovative Medicine:
16,384,000,000 $+6.2%
MedTech:
8,926,000,000 $+3.4%
Total:
25,310,000,000 $+5.2%
Earnings release date:14 Apr. 26
Consumer Health (→ KVUE):
–
Innovative Medicine:
15,426,000,000 $-2.1%
MedTech:
8,636,000,000 $-1.9%
Total:
24,062,000,000 $-2.0%
Earnings release date:21 Jan. 26
Consumer Health (→ KVUE):
–
Innovative Medicine:
15,763,000,000 $+1.3%
MedTech:
8,801,000,000 $+4.4%
Total:
24,564,000,000 $+2.4%
Earnings release date:14 Oct. 25
Consumer Health (→ KVUE):
–
Innovative Medicine:
15,563,000,000 $+2.4%
MedTech:
8,430,000,000 $-1.3%
Total:
23,993,000,000 $+1.1%
Earnings release date:16 Jul. 25
Consumer Health (→ KVUE):
–
Innovative Medicine:
15,202,000,000 $+9.6%
MedTech:
8,541,000,000 $+6.5%
Total:
23,743,000,000 $+8.5%
Earnings release date:15 Apr. 25
Consumer Health (→ KVUE):
–
Innovative Medicine:
13,873,000,000 $-3.2%
MedTech:
8,020,000,000 $-2.1%
Total:
21,893,000,000 $-2.8%
Earnings release date:22 Jan. 25
Consumer Health (→ KVUE):
–
Innovative Medicine:
14,332,000,000 $-1.7%
MedTech:
8,188,000,000 $+3.8%
Total:
22,520,000,000 $+0.2%
Earnings release date:15 Oct. 24
Consumer Health (→ KVUE):
–
Innovative Medicine:
14,580,000,000 $+0.6%
MedTech:
7,891,000,000 $-0.8%
Total:
22,471,000,000 $+0.1%
Earnings release date:17 Jul. 24
Consumer Health (→ KVUE):
–
Innovative Medicine:
14,490,000,000 $+6.8%
MedTech:
7,957,000,000 $+1.7%
Total:
22,447,000,000 $+5.0%
Earnings release date:16 Apr. 24
Consumer Health (→ KVUE):
–
Innovative Medicine:
13,562,000,000 $-1.2%
MedTech:
7,821,000,000 $+1.9%
Total:
21,383,000,000 $-0.1%
Earnings release date:23 Jan. 24
Consumer Health (→ KVUE):
–
Innovative Medicine:
13,722,000,000 $-1.2%
MedTech:
7,673,000,000 $+2.9%
Total:
21,395,000,000 $+0.2%
Earnings release date:17 Oct. 23
Consumer Health (→ KVUE):
–
Innovative Medicine:
13,893,000,000 $+1.2%
MedTech:
7,458,000,000 $-4.2%
Total:
21,351,000,000 $-16.4%
Earnings release date:20 Jul. 23
Consumer Health (→ KVUE):
4,011,000,000 $+4.1%
Innovative Medicine:
13,731,000,000 $+2.4%
MedTech:
7,788,000,000 $+4.1%
Total:
25,530,000,000 $+3.2%
Earnings release date:18 Apr. 23
Consumer Health (→ KVUE):
3,852,000,000 $+2.3%
Innovative Medicine:
13,413,000,000 $+1.9%
MedTech:
7,481,000,000 $+10.4%
Total:
24,746,000,000 $+4.4%
Earnings release date:24 Jan. 23
Consumer Health (→ KVUE):
3,767,000,000 $-0.7%
Innovative Medicine:
13,163,000,000 $-0.4%
MedTech:
6,776,000,000 $-0.1%
Total:
23,706,000,000 $-0.4%
Earnings release date:18 Oct. 22
Consumer Health (→ KVUE):
3,795,000,000 $-0.3%
Innovative Medicine:
13,214,000,000 $-0.8%
MedTech:
6,782,000,000 $-1.7%
Total:
23,791,000,000 $-1.0%
Earnings release date:19 Jul. 22
Consumer Health (→ KVUE):
3,805,000,000 $
Innovative Medicine:
13,317,000,000 $
MedTech:
6,898,000,000 $
Total:
24,020,000,000 $

Revenue by geographic location

Revenue by geographic locationTable view

Earnings release date
United States
Europe
Western Hemisphere excluding U.S.
Asia-Pacific, Africa
Total
Earnings release date:15 Jul. 26
United States:
14,533,000,000 $+9.0%
Europe:
5,726,000,000 $-2.1%
Western Hemisphere excluding U.S.:
1,309,000,000 $+1.2%
Asia-Pacific, Africa:
3,742,000,000 $+4.2%
Total:
25,310,000,000 $+5.2%
Earnings release date:14 Apr. 26
United States:
13,330,000,000 $-6.1%
Europe:
5,848,000,000 $+4.5%
Western Hemisphere excluding U.S.:
1,293,000,000 $+1.7%
Asia-Pacific, Africa:
3,591,000,000 $+2.6%
Total:
24,062,000,000 $-2.0%
Earnings release date:21 Jan. 26
United States:
14,195,000,000 $+3.6%
Europe:
5,598,000,000 $+2.9%
Western Hemisphere excluding U.S.:
1,271,000,000 $+3.2%
Asia-Pacific, Africa:
3,500,000,000 $-3.2%
Total:
24,564,000,000 $+2.4%
Earnings release date:14 Oct. 25
United States:
13,708,000,000 $+1.2%
Europe:
5,440,000,000 $+1.0%
Western Hemisphere excluding U.S.:
1,231,000,000 $+2.1%
Asia-Pacific, Africa:
3,614,000,000 $+0.2%
Total:
23,993,000,000 $+1.1%
Earnings release date:16 Jul. 25
United States:
13,544,000,000 $+10.1%
Europe:
5,387,000,000 $+5.4%
Western Hemisphere excluding U.S.:
1,206,000,000 $+3.3%
Asia-Pacific, Africa:
3,606,000,000 $+8.9%
Total:
23,743,000,000 $+8.5%
Earnings release date:15 Apr. 25
United States:
12,305,000,000 $-6.8%
Europe:
5,110,000,000 $+3.8%
Western Hemisphere excluding U.S.:
1,167,000,000 $+2.8%
Asia-Pacific, Africa:
3,311,000,000 $+1.6%
Total:
21,893,000,000 $-2.8%
Earnings release date:22 Jan. 25
United States:
13,204,000,000 $+2.3%
Europe:
4,921,000,000 $+0.1%
Western Hemisphere excluding U.S.:
1,135,000,000 $-3.2%
Asia-Pacific, Africa:
3,260,000,000 $-6.2%
Total:
22,520,000,000 $+0.2%
Earnings release date:15 Oct. 24
United States:
12,909,000,000 $+2.7%
Europe:
4,914,000,000 $-5.8%
Western Hemisphere excluding U.S.:
1,173,000,000 $-3.2%
Asia-Pacific, Africa:
3,475,000,000 $+0.7%
Total:
22,471,000,000 $+0.1%
Earnings release date:17 Jul. 24
United States:
12,569,000,000 $+8.2%
Europe:
5,214,000,000 $+1.0%
Western Hemisphere excluding U.S.:
1,212,000,000 $+1.5%
Asia-Pacific, Africa:
3,452,000,000 $+1.4%
Total:
22,447,000,000 $+5.0%
Earnings release date:16 Apr. 24
United States:
11,620,000,000 $-3.2%
Europe:
5,163,000,000 $+4.1%
Western Hemisphere excluding U.S.:
1,194,000,000 $+2.4%
Asia-Pacific, Africa:
3,406,000,000 $+4.5%
Total:
21,383,000,000 $-0.1%
Earnings release date:23 Jan. 24
United States:
12,009,000,000 $+0.1%
Europe:
4,962,000,000 $+5.0%
Western Hemisphere excluding U.S.:
1,166,000,000 $-0.4%
Asia-Pacific, Africa:
3,258,000,000 $-5.8%
Total:
21,395,000,000 $+0.2%
Earnings release date:17 Oct. 23
United States:
11,996,000,000 $-10.8%
Europe:
4,727,000,000 $-19.8%
Western Hemisphere excluding U.S.:
1,171,000,000 $-31.6%
Asia-Pacific, Africa:
3,457,000,000 $-22.8%
Total:
21,351,000,000 $-16.4%
Earnings release date:20 Jul. 23
United States:
13,444,000,000 $+7.4%
Europe:
5,894,000,000 $-6.9%
Western Hemisphere excluding U.S.:
1,713,000,000 $+7.9%
Asia-Pacific, Africa:
4,479,000,000 $+3.9%
Total:
25,530,000,000 $+3.2%
Earnings release date:18 Apr. 23
United States:
12,517,000,000 $+0.0%
Europe:
6,332,000,000 $+8.9%
Western Hemisphere excluding U.S.:
1,587,000,000 $+2.7%
Asia-Pacific, Africa:
4,310,000,000 $+12.6%
Total:
24,746,000,000 $+4.4%
Earnings release date:24 Jan. 23
United States:
12,516,000,000 $+0.5%
Europe:
5,816,000,000 $+5.3%
Western Hemisphere excluding U.S.:
1,545,000,000 $-1.1%
Asia-Pacific, Africa:
3,829,000,000 $-9.9%
Total:
23,706,000,000 $-0.4%
Earnings release date:18 Oct. 22
United States:
12,453,000,000 $+2.1%
Europe:
5,524,000,000 $-9.2%
Western Hemisphere excluding U.S.:
1,562,000,000 $+1.7%
Asia-Pacific, Africa:
4,252,000,000 $+1.2%
Total:
23,791,000,000 $-1.0%
Earnings release date:19 Jul. 22
United States:
12,197,000,000 $
Europe:
6,085,000,000 $
Western Hemisphere excluding U.S.:
1,536,000,000 $
Asia-Pacific, Africa:
4,202,000,000 $
Total:
24,020,000,000 $

Operating expenses

Operating expensesTable view

Earnings release date
Cost of products sold
Selling, marketing and administrative
Research and development
In-process R&D impairments
Restructuring
Total
Earnings release date:15 Jul. 26
Cost of products sold:
8,051,000,000 $-0.7%
Selling, marketing and administrative:
6,432,000,000 $+6.6%
Research and development:
3,653,000,000 $+3.6%
In-process R&D impairments:
–
Restructuring:
34,000,000 $+6.3%
Total:
18,170,000,000 $+2.5%
Earnings release date:14 Apr. 26
Cost of products sold:
8,106,000,000 $+1.7%
Selling, marketing and administrative:
6,034,000,000 $-10.6%
Research and development:
3,527,000,000 $-17.1%
In-process R&D impairments:
36,000,000 $-55.6%
Restructuring:
32,000,000 $-61.9%
Total:
17,735,000,000 $-7.3%
Earnings release date:21 Jan. 26
Cost of products sold:
7,968,000,000 $+9.1%
Selling, marketing and administrative:
6,753,000,000 $+14.0%
Research and development:
4,252,000,000 $+15.8%
In-process R&D impairments:
81,000,000 $
Restructuring:
84,000,000 $+33.3%
Total:
19,138,000,000 $+12.8%
Earnings release date:14 Oct. 25
Cost of products sold:
7,303,000,000 $-4.3%
Selling, marketing and administrative:
5,922,000,000 $+0.6%
Research and development:
3,672,000,000 $+4.4%
In-process R&D impairments:
–
Restructuring:
63,000,000 $-1.6%
Total:
16,960,000,000 $-0.8%
Earnings release date:16 Jul. 25
Cost of products sold:
7,628,000,000 $+3.7%
Selling, marketing and administrative:
5,889,000,000 $+15.2%
Research and development:
3,516,000,000 $+9.0%
In-process R&D impairments:
–
Restructuring:
64,000,000 $+276.5%
Total:
17,097,000,000 $+8.8%
Earnings release date:15 Apr. 25
Cost of products sold:
7,357,000,000 $+3.2%
Selling, marketing and administrative:
5,112,000,000 $-20.8%
Research and development:
3,225,000,000 $-39.1%
In-process R&D impairments:
–
Restructuring:
17,000,000 $-59.5%
Total:
15,711,000,000 $-17.0%
Earnings release date:22 Jan. 25
Cost of products sold:
7,128,000,000 $+2.4%
Selling, marketing and administrative:
6,453,000,000 $+17.8%
Research and development:
5,298,000,000 $+7.0%
In-process R&D impairments:
17,000,000 $
Restructuring:
42,000,000 $+2.4%
Total:
18,938,000,000 $+8.6%
Earnings release date:15 Oct. 24
Cost of products sold:
6,963,000,000 $+1.4%
Selling, marketing and administrative:
5,478,000,000 $-3.6%
Research and development:
4,952,000,000 $+44.0%
In-process R&D impairments:
–
Restructuring:
41,000,000 $+415.4%
Total:
17,434,000,000 $+7.8%
Earnings release date:17 Jul. 24
Cost of products sold:
6,869,000,000 $+5.5%
Selling, marketing and administrative:
5,681,000,000 $+8.1%
Research and development:
3,440,000,000 $-2.9%
In-process R&D impairments:
194,000,000 $
Restructuring:
-13,000,000 $-107.9%
Total:
16,171,000,000 $+4.5%
Earnings release date:16 Apr. 24
Cost of products sold:
6,511,000,000 $-4.2%
Selling, marketing and administrative:
5,257,000,000 $-9.5%
Research and development:
3,542,000,000 $-20.9%
In-process R&D impairments:
–
Restructuring:
164,000,000 $+192.9%
Total:
15,474,000,000 $-10.0%
Earnings release date:23 Jan. 24
Cost of products sold:
6,798,000,000 $+2.9%
Selling, marketing and administrative:
5,810,000,000 $+7.6%
Research and development:
4,480,000,000 $+30.0%
In-process R&D impairments:
58,000,000 $-71.8%
Restructuring:
56,000,000 $-64.6%
Total:
17,202,000,000 $+8.8%
Earnings release date:17 Oct. 23
Cost of products sold:
6,606,000,000 $-19.6%
Selling, marketing and administrative:
5,400,000,000 $-19.0%
Research and development:
3,447,000,000 $-10.0%
In-process R&D impairments:
206,000,000 $
Restructuring:
158,000,000 $+9.0%
Total:
15,817,000,000 $-16.1%
Earnings release date:20 Jul. 23
Cost of products sold:
8,212,000,000 $-2.2%
Selling, marketing and administrative:
6,665,000,000 $+8.6%
Research and development:
3,829,000,000 $+7.5%
In-process R&D impairments:
–
Restructuring:
145,000,000 $+11.5%
Total:
18,851,000,000 $+3.2%
Earnings release date:18 Apr. 23
Cost of products sold:
8,395,000,000 $+8.1%
Selling, marketing and administrative:
6,138,000,000 $-5.7%
Research and development:
3,563,000,000 $-7.2%
In-process R&D impairments:
49,000,000 $-71.7%
Restructuring:
130,000,000 $+54.8%
Total:
18,275,000,000 $-0.5%
Earnings release date:24 Jan. 23
Cost of products sold:
7,765,000,000 $-0.5%
Selling, marketing and administrative:
6,512,000,000 $+6.9%
Research and development:
3,841,000,000 $+6.8%
In-process R&D impairments:
173,000,000 $
Restructuring:
84,000,000 $+2.4%
Total:
18,375,000,000 $+4.6%
Earnings release date:18 Oct. 22
Cost of products sold:
7,807,000,000 $-1.4%
Selling, marketing and administrative:
6,089,000,000 $-2.2%
Research and development:
3,597,000,000 $-2.9%
In-process R&D impairments:
–
Restructuring:
82,000,000 $-3.5%
Total:
17,575,000,000 $-2.0%
Earnings release date:19 Jul. 22
Cost of products sold:
7,919,000,000 $
Selling, marketing and administrative:
6,226,000,000 $
Research and development:
3,703,000,000 $
In-process R&D impairments:
–
Restructuring:
85,000,000 $
Total:
17,933,000,000 $

Profitability

ProfitabilityTable view

Earnings release date
Net income (shareholders)
Free cash flow
Total
Earnings release date:15 Jul. 26
Net income (shareholders):
5,534,000,000 $+5.7%
Free cash flow:
7,295,000,000 $+398.0%
Total:
12,829,000,000 $+91.5%
Earnings release date:14 Apr. 26
Net income (shareholders):
5,235,000,000 $+2.3%
Free cash flow:
1,465,000,000 $-73.2%
Total:
6,700,000,000 $-36.7%
Earnings release date:21 Jan. 26
Net income (shareholders):
5,116,000,000 $-0.7%
Free cash flow:
5,472,000,000 $-31.7%
Total:
10,588,000,000 $-19.6%
Earnings release date:14 Oct. 25
Net income (shareholders):
5,152,000,000 $-7.0%
Free cash flow:
8,012,000,000 $+182.6%
Total:
13,164,000,000 $+57.2%
Earnings release date:16 Jul. 25
Net income (shareholders):
5,537,000,000 $-49.7%
Free cash flow:
2,835,000,000 $-16.1%
Total:
8,372,000,000 $-41.8%
Earnings release date:15 Apr. 25
Net income (shareholders):
10,999,000,000 $+220.6%
Free cash flow:
3,379,000,000 $-37.1%
Total:
14,378,000,000 $+63.3%
Earnings release date:22 Jan. 25
Net income (shareholders):
3,431,000,000 $+27.4%
Free cash flow:
5,371,000,000 $-22.9%
Total:
8,802,000,000 $-8.9%
Earnings release date:15 Oct. 24
Net income (shareholders):
2,694,000,000 $-42.5%
Free cash flow:
6,964,000,000 $+49.5%
Total:
9,658,000,000 $+3.4%
Earnings release date:17 Jul. 24
Net income (shareholders):
4,686,000,000 $-12.5%
Free cash flow:
4,657,000,000 $+63.4%
Total:
9,343,000,000 $+13.9%
Earnings release date:16 Apr. 24
Net income (shareholders):
5,354,000,000 $+32.2%
Free cash flow:
2,850,000,000 $-54.6%
Total:
8,204,000,000 $-20.5%
Earnings release date:23 Jan. 24
Net income (shareholders):
4,049,000,000 $-84.4%
Free cash flow:
6,274,000,000 $-3.8%
Total:
10,323,000,000 $-68.3%
Earnings release date:17 Oct. 23
Net income (shareholders):
26,028,000,000 $+406.0%
Free cash flow:
6,522,000,000 $+113.3%
Total:
32,550,000,000 $+296.9%
Earnings release date:20 Jul. 23
Net income (shareholders):
5,144,000,000 $+7664.7%
Free cash flow:
3,058,000,000 $+27.7%
Total:
8,202,000,000 $+252.6%
Earnings release date:18 Apr. 23
Net income (shareholders):
-68,000,000 $-101.9%
Free cash flow:
2,394,000,000 $-36.4%
Total:
2,326,000,000 $-68.1%
Earnings release date:24 Jan. 23
Net income (shareholders):
3,520,000,000 $-21.0%
Free cash flow:
3,763,000,000 $-29.4%
Total:
7,283,000,000 $-25.6%
Earnings release date:18 Oct. 22
Net income (shareholders):
4,458,000,000 $-7.4%
Free cash flow:
5,332,000,000 $+13.0%
Total:
9,790,000,000 $+2.7%
Earnings release date:19 Jul. 22
Net income (shareholders):
4,814,000,000 $
Free cash flow:
4,718,000,000 $
Total:
9,532,000,000 $

Profit margin in %

Profit margin in %Table view

Earnings release date
Profit margin (shareholders)
Profit margin (free cash flow)
Earnings release date:15 Jul. 26
Profit margin (shareholders):
21.86 %+0.1 pp
Profit margin (free cash flow):
28.82 %+22.7 pp
Earnings release date:14 Apr. 26
Profit margin (shareholders):
21.76 %+0.9 pp
Profit margin (free cash flow):
6.09 %-16.2 pp
Earnings release date:21 Jan. 26
Profit margin (shareholders):
20.83 %-0.6 pp
Profit margin (free cash flow):
22.28 %-11.1 pp
Earnings release date:14 Oct. 25
Profit margin (shareholders):
21.47 %-1.8 pp
Profit margin (free cash flow):
33.39 %+21.5 pp
Earnings release date:16 Jul. 25
Profit margin (shareholders):
23.32 %-26.9 pp
Profit margin (free cash flow):
11.94 %-3.5 pp
Earnings release date:15 Apr. 25
Profit margin (shareholders):
50.24 %+35.0 pp
Profit margin (free cash flow):
15.43 %-8.4 pp
Earnings release date:22 Jan. 25
Profit margin (shareholders):
15.24 %+3.2 pp
Profit margin (free cash flow):
23.85 %-7.1 pp
Earnings release date:15 Oct. 24
Profit margin (shareholders):
11.99 %-8.9 pp
Profit margin (free cash flow):
30.99 %+10.2 pp
Earnings release date:17 Jul. 24
Profit margin (shareholders):
20.88 %-4.2 pp
Profit margin (free cash flow):
20.75 %+7.4 pp
Earnings release date:16 Apr. 24
Profit margin (shareholders):
25.04 %+6.1 pp
Profit margin (free cash flow):
13.33 %-16.0 pp
Earnings release date:23 Jan. 24
Profit margin (shareholders):
18.92 %-103.0 pp
Profit margin (free cash flow):
29.32 %-1.2 pp
Earnings release date:17 Oct. 23
Profit margin (shareholders):
121.91 %+101.8 pp
Profit margin (free cash flow):
30.55 %+18.6 pp
Earnings release date:20 Jul. 23
Profit margin (shareholders):
20.15 %+20.4 pp
Profit margin (free cash flow):
11.98 %+2.3 pp
Earnings release date:18 Apr. 23
Profit margin (shareholders):
-0.27 %-15.1 pp
Profit margin (free cash flow):
9.67 %-6.2 pp
Earnings release date:24 Jan. 23
Profit margin (shareholders):
14.85 %-3.9 pp
Profit margin (free cash flow):
15.87 %-6.5 pp
Earnings release date:18 Oct. 22
Profit margin (shareholders):
18.74 %-1.3 pp
Profit margin (free cash flow):
22.41 %+2.8 pp
Earnings release date:19 Jul. 22
Profit margin (shareholders):
20.04 %
Profit margin (free cash flow):
19.64 %